Welcome to the Kids' Library!

Search for books, movies, music, magazines, and more.

Back to Search Results

Available items only

Record 1 of 2

Previous Record Next Record

Author

Donghi, Monica, author.

Title Patent strategy in pharmaceutical industry : are additional patents valuable? / Monica Donghi.

Publication Info.

Baden-Baden : Nomos, 2014.

Connect to
Connect to https://pittstate.idm.oclc.org/login?url=https://www.jstor.org/stable/10.2307/j.ctv941vfr

Copies

Location	Call No.	OPAC Message	Status
Axe JSTOR Open Ebooks	Electronic Book	---	Available

Edition	1. Auflage.
Description	1 electronic resource (84 pages ).
	text txt rdacontent
	computer c rdamedia
	online resource cr rdacarrier
	data file
Series	MIPLC studies ; volume 20
	MIPLC studies ; volume 20.
Note	Originally presented as author's thesis (LL.M.)--Munich Intellectual Property Law Center, 2012.
Bibliography	Includes bibliographical references (pages 77-84).
Note	Description based on print version record; resource not viewed.
Contents	Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices.
	F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German.
	Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others.
Summary	Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20.
Language	English.
Subject	Drugs -- Patents -- Economic aspects -- European Union countries.
	Patent medicines -- Law and legislation -- European Union countries.
	Patent medicines -- European Union countries -- Case studies.
	Drugs -- Patents.
	Médicaments -- Brevets d'invention.
	Médicaments -- Brevets d'invention -- Aspect économique -- Pays de l'Union européenne.
	Spécialités pharmaceutiques -- Pays de l'Union européenne -- Études de cas.
	LAW -- Commercial -- General.
	Patent medicines
	Patent medicines -- Law and legislation
	European Union countries
Indexed Term	Markenrecht
	Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht
	Gewerblicher Rechtsschutz
Genre/Form	Case studies
Other Form:	Print version: Patent strategy in pharmaceutical industry Baden-Baden : Nomos, 2014. 9783848709915 (DLC) 2015372690
ISBN	3848709910
	9783848709915
	9783845251288
	384525128X
Standard No.	AU@ 000056062506
	AU@ 000062534616
	DEBSZ 431647895